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Elevated expression of Annexin II (Lipocortin II, p36) in a multidrug
resistant small cell lung cancer cell line
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Summary The doxorubicin-selected multidrug resistant small cell lung cancer cell line, H69AR, is cross-
resistant to the Vinca alkaloids and epipodophyllotoxins, but does not overexpress P-glycoprotein, a 170 kDa
plasma membrane efflux pump usually associated with this type of resistance. Monoclonal antibodies were
raised against the H69AR cell line and one of these, MAb 3.186, recognises a peptide epitope on a 36 kDa
phosphorylated protein that is membrane associated, but not presented on the external surface of H69AR cells
(Mirski & Cole, 1991). In the present study, in vitro translation and molecular cloning techniques were used to
determine the relative levels of mRNA corresponding to the 3.186 antigen. In addition, a cDNA clone
containing an insert of approximately 1.4 kb was obtained by screening an H69AR cDNA library with
'25I-MAb 3.186. Fragments of this cloned DNA hybridised to a single mRNA species of approximately 1.6kb
that was 5 to 6-fold elevated in H69AR cells. Partial DNA sequencing and restriction endonuclease mapping
revealed identity of the cloned DNA with p36, a member of the annexin/lipocortin family of Ca2l and
phospholipid binding proteins.
The H69AR cell line was derived by selection of the small
cell lung cancer (SCLC) cell line, H69, in doxorubicin (DOX)
(Cole, 1986; Mirski et al., 1987) and is cross-resistant to
other anthracyclines, the Vinca alkaloids and the epipo-
dophyllotoxins (Mirski et al., 1987; Cole, 1990). This pattern
of cross-resistance is typical of cells that express elevated
levels of P-glycoprotein, a plasma membrane glycoprotein
that confers multidrug resistance by enhancing drug efflux
(for reviews see Refs. Deuchars & Ling, 1989; Endicott &
Ling, 1989). However, H69AR cells do not overexpress this
protein as detected by immunoblotting (Mirski et al., 1987)
or by a polymerase chain reaction-based assay (Cole et al.,
1991). Furthermore, transport studies with radiolabelled
daunomycin, VP-16 and vinblastine have shown that drug
accumulation is not reduced in this cell line (Cole et al.,
1991). Thus multidrug resistance in H69AR cells does not
appear to be mediated by P-glycoprotein or a similar trans-
porter and may be multifactorial. In a recent study we
reported that reduced levels of topoisomerase II may con-
tribute to resistance in H69AR cells, but other mechanisms
must be involved to explain the resistance of these cells to the
Vinca alkaloids (Cole et al., 1991). Given the evidence that
overexpression of P-glycoprotein in SCLC is an infrequent
occurrence (Lai et al., 1989; Noonan et al., 1990; Brambilla
et al., 1991), the investigation of drug resistance in H69AR
cells is important because of its potential clinical relevance.
Monoclonal antibodies against P-glycoprotein have facili-
tated the identification and characterisation of the genes
involved in P-glycoprotein-mediated drug resistance (Riordan
et al., 1985) and are playing an important role in elucidating
the functional significance of this protein in clinical drug
resistance (Gerlach et al., 1986). Similarly, the production of
MAbs against antigens overexpressed in H69AR cells seemed
an approach likely to provide useful tools for investigations
of non-P-glycoprotein-mediated multidrug resistance. Thus
we generated a panel of MAbs after immunising mice with
viable H69AR cells (Mirski & Cole, 1989). One of these
MAbs (3.186) recognises a peptide epitope on a 36 kDa
phosphorylated protein that is membrane associated, but not
presented on the external surface of the cell (Mirski & Cole,
1989; Mirski & Cole, 1991). Previously, we have obtained
tentative estimates of the relative levels of the 3.186 antigen
in the sensitive H69 and resistant H69AR cell lines by
indirect immunoassays (Mirski & Cole, 1989). These esti-
mates indicated that H69AR cells express approximately
three-fold more 3.186 antigen than H69 cells. In the present
study, we have used in vitro translation and molecular clon-
ing techniques to determine the relative levels of mRNA
corresponding to the 3.186 antigen. We have also cloned a
full-length cDNA for the 3.186 antigen and demonstrated by
partial DNA sequencing and restriction endonuclease map-
ping its identity with p36, a member ofthe annexin/lipocortin
family of Ca2" and phospholipid binding proteins.
Materials and methods
Cell culture
The SCLC cell line NCl-H69 (H69) was provided by Drs J.
Minna and A. Gazdar (NCl-Navy Medical Oncology Branch,
NIH, Bethesda, MD). The H69AR cell line is a multidrug
resistant derivative of H69 that is approximately 50-fold
resistant to DOX, but does not overexpress P-glycoprotein
(Mirski et al., 1987; Cole et al., 1991). The H69PR cell line
('PR', previously resistant) is a revertant of the H69AR cell
line that has regained sensitivity to DOX, VP-16 and vincris-
tine. It was obtained after continuous culture of the H69AR
cell line in drug-free medium for more than 37 months. All
three cell lines were grown in the absence of antibiotics in
glass bottles in RPMI 1640 medium (GIBCO, Burlington,
Ont.) supplemented with 5% supplemented defined bovine
serum (Hyclone Laboratories Inc., Logan, UT) and 4 mM
L-glutamine. The cell lines were negative for mycoplasma
contamination.
Monoclonal antibody 3.186
The derivation and reactivity of MAb 3.186 (IgG,) has been
described previously (Mirski & Cole, 1989; Mirski & Cole,
1991). MAb 3.186 was enriched from crude ascites by protein
A affinity chromatography using MAPSTm (BioRad Labor-
atories, Mississauga, Ont.) and concentrated using a Cen-
tricon-10 filter (Amicon Canada Ltd., Oakville, Ont.).
MAb 3.186 was radioiodinated with Todobeads' (Pierce,
Rockford, IL) and Na'251 (2000 Cimmolh', carrier free in
NaOH; ICN Biomedical, Mississauga, Ont.) to a specific
activity of > 5 x 0I c.p.m. iig-I protein (Markwell, 1982).
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In vitro Translations and immunoprecipitations
In vitro translations were carried out using a rabbit reticulo-
cyte lysate (cell free) translation system (Promega Corpora-
tion, Madison, WI) and "5S-methionine (translation grade,
800 Ci mmol-'; Dupont/NEN, Mississauga, Ont.) (Mirski &
Cole, 1991). "S-labelled in vitro translation products were
immunoprecipitated with Protein A Sepharose CL-4B beads
(Pharmacia, Baie d'Urfe, Que.) and rabbit anti-mouse Igs
(Dimension Laboratories, Mississauga, Ont.) as described
(Mirski & Cole, 1991). Immunoprecipitates were subjected to
electrophoresis on 10% sodium dodecyl sulfate (SDS)-poly-
acrylamide gels. The gels were fixed, soaked in Amplify"
(Amersham, Oakvill, Ont.), dried and exposed to Kodak
X-AR film at - 70°C with intensifying screens.
cDNA library construction and screening
Poly (A') RNA was isolated from H69AR cells using a Fast
TrackrM mRNA isolation kit (Invitrogen, San Diego, CA).
Beginning with 5 tLg of H69AR mRNA, an oligo-dT primed
size-selected cDNA library of approximately 2 x 106 indepen-
dent recombinant Agtl1 phage was prepared using a cDNA
synthesis and cloning kit (Amersham Corporation, Toronto,
Ont.). The majority ofcDNA inserts were in the range of 500
to 1500 bp. After amplification, 5 x 105 plaques were screen-
ed on nitrocellulose plaque lifts by standard techniques with
'25I-MAb 3.186 (1 x 106 c.p.m. ml-') diluted in 5% non-fat
dried milk in PBS. Immunoreactive plaques were identified
by autoradiography and were plaque purified by subsequent
rounds of screening at decreasing plaque density until all
plaques reacted with '251-MAb 3.186.
Subcloning, restriction enzyme analysis and DNA sequencing
The A DNA was purified as described by Davis et al. (1986)
and the cDNA inserts of the positive clones were subcloned
into the phagemid vector pGEMt-3Zf(+) (Promega). Re-
striction enzyme mapping was carried out with restriction
enzymes from Pharmacia and GIBCO/BRL. Portions of the
cDNA inserts were sequenced by the dideoxynucleotide
method (Sanger et al., 1977) with the SequenaseTM (version
2.0) modified T7 DNA polymerase (United States Biochem-
ical, Cleveland, OH) using `S-dATP (1315 Ci mmol ', Du-
pont/NEN).
Northern blot and slot blot analyses
Poly(A+) RNA (1 gg) or total RNA (30fig) was subjected to
electrophoresis on a 1% agarose gel containing fomaldehyde
and transferred to BioTransM nylon membrane (ICN Bio-
medical) or nitrocellulose membrane (Schleicher & Schuell,
Keene, NH) by capillary action (Sambrook et al., 1989). The
blot was prehybridised in 50% formamide, 5 x SSPE
(1 x = 150mM NaCl, 10mM NaH2PO4, 1 mM EDTA, pH
7.4), 2.5 x Denhardt's solution (50 x = 1% bovine serum
albumin, 1% polyvinylpyrrolidine, 1% Ficoll), 0.1% SDS
and sheared, denatured herring testes DNA (100 gLg ml-').
cDNA probes, labelled to a specific activity of >5 x 108
c.p.m.Ag-' DNA with x-32P-dATP (3000 Ci mmolh ; Du-
pont/NEN) by the random priming method (Feinberg &
Vogelstein, 1983) or by nick translation (Sambrook et al.,
1989), were added directly to the blot in the prehybridisation
solution. Prehybridisations and hybridisations were carried
out at 42°C for 8-16 h. Blots were washed four times in
0.1% SDS and 0.1 x SSC (1 x = 150mM NaCl, 15 mM
sodium citrate, pH 7.0) for 15 min each at 52°C. The temp-
erature was raised to increase stringency as required. The
P-actin cDNA (201 pBV2.2) (Ueyama et al., 1984) and rRNA
probes were used to verify equal loading of gels. For slot blot
analysis, RNA samples were denatured in 1.25 x SSC and
40% formamide for 15 min at 65°C before being applied to a
prewetted (10 x SSC for 10 min) nylon membrane in a slot
blot apparatus under vacuum. The RNA was fixed to the
membrane by baking at 80°C in vacuo and the membranes
probed as above. Densitometry was performed using an HSI
GS-300 Scanning Densitometer (Hoefer Scientific Instru-
ments, San Francisco, CA).
Results
In vitro translation and immunoprecipitations
The relative levels of mRNA corresponding to the 3.186
antigen were compared by immunoprecipitation ofequivalent
amounts of "5S-methionine labelled in vitro translation prod-
ucts of RNA from both H69 and H69AR cells. Densitometry
of autoradiographs showed that 5 to 6-fold more of the
36 kDa antigen was immunoprecipitated from the translation
products of H69AR mRNA relative to H69 (Figure 1). These
results indicate a 5 to 6-fold difference in mRNA levels,
assuming that the mRNA for the 3.186 antigen is translated
with comparable efficiency in RNA preparations from both
the H69 and H69AR cell lines.
Isolation and characterisation of3.186 cDNA clones
To further characterise the 3.186 mRNA and its levels of
expression, cDNA clones were isolated from an H69AR
cDNA library by screening with '25I-MAb 3.186. Three
positive clones were obtained after secondary screening and
plaque purification. All three clones contained inserts of
approximately 1.4 kb with a single internal EcoRI site.
Digestion with this enzyme yielded fragments of approx-
imately 1.0 and 0.4 kb in all three cases. The presence of an
internal EcoRI site was not unexpected because EcoRI adap-
tors (which obviate the need for EcoRI digestion of the
cDNA prior to insertion in the vector) were used in the
cloning procedure. The possibility that the internal EcoRI
site resulted from artifactual cloning of two fragments was
eliminated by the DNA sequencing results as described
below. The two EcoRI fragments from the inserts of all
three clones were subcloned into the phagemid vector
pGEM®-3Zf(+). They were then used as probes for RNA
blotting analyses and sequencing studies.
Northern blot analysis of H69 and H69AR total and
poly(A+) RNA showed hybridization with a single mRNA
species of approximatelyl.4-1.6 kb (Figure 2). Densitometry
showed 5 to 6-fold higher levels of this mRNA in H69AR
cells relative to H69. Equal loading of RNA samples on the
gel was confirmed by stripping and probing of the northern
blot with a 32P-labelled P-actin cDNA probe (data not





Figure 1 MAb 3.186 immunoprecipitations of 35S-methionine
labelled in vitro translation products. Lanes 1 and 4, total transla-
tion products from H69 and H69AR mRNA, respectively; lanes 2
and 3 MAb 3.186 immunoprecipitations of translation products
from H69 and H69AR mRNA, respectively. The position of the
36 kDa 3.186 antigen is indicated on the right and the position of
the molecular weight markers (kDa) is indicated on the left.Acci
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Figure 3 Summary map of the 1.4 kb cDNAs isolated from an
H69AR cDNA library with MAb 3.186. The hatched bars are the
1.0 and 0.4 kb EcoRI subclones (designated MJ3 and MJ8,
respectively) and the arrows indicate the portions of the cDNA
that were sequenced. The restriction enzyme sites are indicated by
the solid vertical lines. The stippled bar is the coding sequence of
the p36 cDNA while the horizontal lines to the left and the right
of the stippled bar are non-coding regions.
Table I Relative resistance of the H69, H69AR and H69PR cell
lines
IC50 ylM (fold-resistant)
Cell line DOX VP-16 Vincristine
H69 0.095 5.4 0.01
H69AR 6.0 (63) >30 (>6) 1 (100)
H69PR 0.33 (3.5) 7 (1.3) 0.018 (1.8)
Figure 2 Northern blot analysis of RNAs from H69 and
H69AR cells. Poly(A)+ RNA (1 sg) and total RNA (30tsg) were
separated by agarose gel electrophoresis and blotted to a nylon
membrane. The blot was probed with the 1.0 kb EcoRI subclone
of the 3.186 cDNA clone, stripped and reprobed with a P-actin
cDNA. Levels of the mRNA that hybridised specifically with the
1.0 kb cDNA were estimated by densitometry and the size of the
mRNA was estimated by comparison with an RNA size ladder.
shown). The relative levels of mRNA corresponding to the
3.186 antigen shown by northern blotting are in reasonable
agreement with those obtained by immunoprecipitation of in
vitro translation products (Figure 1).
Partial double stranded cDNA sequencing of the sub-
cloned 1.0 and 0.4 kb EcoRI fragments indicated that the
three clones isolated were derived from the same cDNA
insert. A search of the GenBank DNA sequence database
revealed a perfect match with human calpactin I (heavy
chain) (accession # M14043) (Saris et al., 1986) and lipocor-
tin II (accession # A23942) (Huang et al., 1986), proteins
also known as annexin II and p36. Further confirmation of
the identity of the 3.186 cDNA clone was obtained by restric-
tion endonuclease mapping with AccI, NdeI, HincIl, Hin-
dIll, PstI and XbaI. In all cases, digestion with these
enzymes generated fragments with sizes that were in accord-
ance with those predicted from the established sequence of
p36. These data are summarised in Figure 3.
Comparison of3.186 mRNA levels in H69, H69AR and
H69PR cells
Shortly after cloning the cDNAs corresponding to the 3.186
antigen, we succeeded in isolating a revertant of the H69AR
cell line, designated H69PR, after very long term culture
(>37 months) of H69AR cells in drug-free medium. The
sensitivity of the revertant H69PR cells to DOX, vincristine
and VP-16 approaches that of the sensitive H69 cells (Table
1). Therefore we were able to compare 3.186 protein and
mRNA levels in the H69PR cell line to those in the H69 and
H69AR cell lines. Immunoblot analysis and flow cytometry
showed comparable amounts of 3.186 protein in H69AR and
H69PR cells (results not shown). Immunoprecipitation of in
vitro translation products of RNA from the H69, H69AR
and H69PR cell lines indicated that the levels of 3.186
mRNA in H69PR were the same as that seen in H69AR
(Figure 4, panel a). Northern (Figure 4, panel b) and slot
blot (Figure 4, panel c) analyses of the three cell lines also
showed that levels of 3.186 mRNA were comparable in the
resistant H69AR and revertant H69PR cell lines. The slight
decrease in 3.186 mRNA in the H69PR cell line observed in
the northern blot (Figure 4, panel b) is attributable to an
underloading of H69PR RNA as indicated by the relative
amounts of 28S rRNA.
Discussion
The H69AR cell line is one of an increasing number of cell
lines that displays multidrug resistance in the absence of
elevated levels of P-glycoprotein (Mirski et al., 1987; Slovak
et al., 1988; de Jong et al., 1990; Baas et al., 1990; Reeve et
al., 1990; Slapak et al., 1990; Cass et al., 1989). We have
derived four MAbs that detect antigens overexpressed in
H69AR cells as a means of identifying proteins that may be
involved in the resistance mechanism of these cells (Mirski &











Figure 4 Analyses of relative p36 mRNA levels in the H69,
H69AR and H69PR cell lines. Panel a, MAb 3.186 immunopre-
cipitation of in vitro translated mRNA; panel b, Northern blot
analysis with the 1.0kb 3.186 cDNA subclone MJ3 and 28S
rRNA; panel c, slot blot analysis of RNA hybridised with MJ3
and 28S rRNA.
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study was to determine whether the increased expression of
the 3.186 antigen was a consequence of enhanced synthesis as
reflected by elevated levels of its mRNA. The in vitro transla-
tion and immunoprecipitation experiments confirmed that
this was the case (Figure 1). Our second objective was to
further characterise the 3.186 mRNA and protein by isola-
tion of 3.186 cDNA clones. The clone isolated by screening a
H69AR cDNA expression library with MAb 3.186 contained
an insert of approximately 1.4 kb. Fragments of the cloned
DNA hybridized with a single mRNA size class also of
approximately 1.4 kb (Figure 2), suggesting that the cDNA
was essentially full length. DNA sequencing of three different
regions of the clone revealed complete identity with the
published sequence of human calpactin I (Saris et al., 1986)
and the GenBank database sequence of lipocortin II, proteins
also referred to as p36 and annexin II. Restriction endo-
nuclease analysis also demonstrated complete consistency
with sites predicted from the DNA sequence of p36 (Figure
3). The conclusion that the 3.186 antigen is identical to p36 is
further supported by the known biochemical properties of
these two proteins, viz., the sizes of the polypeptides are
identical, both can be phosphorylated and are not detectably
N-glycosylated (Mirski & Cole, 1991; Mel'gunov, 1991) and
both can be detected in association with various cellular
membranes. The 3.186 antigen has also been detected on the
human colon carcinoma WiDR cell line and peripheral blood
mononuclear cells (Mirski & Cole, 1991; Krebes et al., 1991)
as has p36 (Frohlich et al., 1990; Rothhut et al., 1987).
Taken together, our data provide convincing evidence that
the antigen reacting with MAb 3.186 is identical to p36 and
that p36 synthesis is elevated in the multidrug resistant
H69AR cell line.
p36 belongs to a family of calcium and phospholipid bind-
ing proteins that consists of at least eight members. These
proteins are known by several names including annex-
ins, lipocortins, calpactins, chromobindins, and calelectrins
(Crumpton & Dedman, 1990; Russo-Marie, 1991). The var-
ious annexins are very similar proteins suggesting overlap-
ping activities. However, distinct differences in some aspects
of their structure and in their cellular and intracellular
localisation indicate that each protein is likely to have a
specialised function as well (Pepinsky et al., 1988; Ernst et
al., 1991; Glenney et al., 1987). All members of the annexin
family have a core consisting of four repeated units of ap-
proximately 70 amino acids that contain phospholipid and
calcium binding sites. The NH2-terminal tails of the annexins
are quite variable in sequence and length. In p36 (annexin
II), this region contains both serine and tyrosine phos-
phorylation sites (Glenney & Tack, 1985; Gerke, 1989) and
p36 has been shown to be a substrate for pp6Ov-src (Huang et
al., 1986; Erikson et al., 1984; Saris et al., 1986) and protein
kinase C (Gould et al., 1986; Barnes et al., 1991).
Although much is known about the molecular and bio-
chemical properties of p36, its true physiological functions
remain uncertain (Gerke, 1989; Crompton et al., 1988;
Mel'gunov, 1991). p36 exists as either a monomer or as a
heterotetramer with an 11 kDa protein, pll, forming a
(p36)2(p1l)2 complex (Erikson et al., 1984; Glenney & Tack,
1985; Johnsson et al., 1988; Glenney et al., 1986; Zokas &
Glenney, 1987). In the latter form, it may be a structural
component of the cytoskeletal framework. In addition, p36
has been implicated in a number of cellular events, including
signal transduction through inhibition of phospholipase A2
(Davidson et al., 1987; Brugge, 1986), DNA lagging strand
synthesis (Jindal et al., 1991) and exocytosis (Burgoyne,
1991). Finally, increased expression of p36 has been assoc-
iated with transformation (Frohlich et al., 1990) and
differentiation (Isacke et al., 1989; Tox et al., 1991).
The functional significance of the overexpression of p36
with respect to drug resistance remains unknown. Previously,
we examined a panel of fifteen paired drug-sensitive and
-resistant tumour cell lines derived from a variety of tissues
by a cell ELISA but found no resistance-associated overex-
pression of the 3.186 antigen (Mirski & Cole, 1991). Further-
more, comparative analyses of p36 mRNA and protein levels
in H69 and H69AR cell lines with the recently obtained
H69PR revertant cell line indicate that recovery of drug
sensitivity is not accompanied by any grossly apparent de-
crease in the synthesis of p36 (Figure 4). However, the full
implications of these findings are unclear. At present, we do
not know whether the acquisition of resistance in H69AR
cells or reversion to drug sensitivity in H69PR cells is
associated with altered post-translational modifications of
p36 (e.g. phosphorylation levels) and/or with altered intracel-
lular localisation of p36. In this regard, a recent study in
which the p36 protein was shown to be identical to the
primer recognition protein 1 (PRP1) is of interest. PRP1
(p36) associates with the glycolytic enzyme 3-phosphogly-
cerate kinase (PRP2) to form a complex that interacts with
DNA polymerase a (Jindal et al., 1991) and thus p36 may
play a major role in the coordination of leading and lagging
strand DNA synthesis. It is worth noting that this important
function involves less than 5% of the total cellular p36.
Consequently, alterations in the amounts and/or phosphory-
lation of nuclear p36 could significantly affect DNA synthesis
through PRP1 function without the total cellular p36 being
detectably affected. Slight alterations in the subcellular dist-
ribution of p36 could similarly affect lagging strand DNA
synthesis. Of further interest is the preliminary report of
alterations in another annexin, annexin I (p35), in a murine
DOX-selected multidrug resistant cell line (Bhushan & Trit-
ton, 1991). In this case, the sensitive and resistant cell lines
do not differ in their levels of p35 protein but in their degree
of p35 phosphorylation. These investigators have postulated
that phosphorylation of p35 by protein tyrosine kinases, with
consequent effects on phospholipase A2, may play a role in
regulating the multidrug resistance phenotype. Thus some
activities of p36 that may relate to drug resistance could be
modulated by the level of phosphorylation and/or subcellular
localisation of the protein. For this reason, comparative
analyses of the phosphorylation status and intracellular dis-
tribution of p36 in the H69, H69AR and H69PR cell lines
are the subject of ongoing investigations.
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